Following Yale Investigator-Led Trials, FDA Approves First Drug to Delay Onset of Type 1 Diabetes

The FDA approved teplizumab, the first drug with the ability to change the course of type 1 diabetes, or any autoimmune disease. Yale School of Medicine played a crucial role in the drug’s trials, most of which were led by Dr. Kevan Herold, Long Professor of Immunobiology and of Medicine